


**Medtronic**

Engineering the extraordinary

Pipeline™ Vantage

Embolization device with shield technology™

# The Vantage response




# Reduced material thrombogenicity

By covalently bonding phosphorylcholine to the surface of the implant, Shield Technology™ achieves a scientifically proven reduction in implant material thrombogenicity, thereby reducing blood contact activation in-vitro.<sup>1-5</sup>


## Promotes flow diversion effect

Endothelialization is important to the success of flow diversion therapy. Pipeline™ Vantage focuses on 3 key areas that promote the flow diversion effect.


**Optimized pore density\***



**Optimized wall thickness\***



**Optimized wall apposition\***



Maintain proven metal to vessel coverage of Pipeline™

# More control, precise delivery

Improvements to both the device and delivery system provides **more control** during navigation, deployment and re-sheathing so you can achieve a **precise delivery**, when treating aneurysms near and far.

## Key design features\*:

- Advanced Re-sheathing mechanism for **reduced friction**
- Single core wire for **increased pushability** and **stability**
- 44% thinner ePTFE sleeves for **faster distal braid release**
- Compatible with Phenom™ 21 Catheter for **easier distal access**
- Compatible with Rist™ Radial Access Guide Catheter **make the turn**

\*When compared to Pipeline™ Flex with Shield Technology™

2022

- ✓ 4th Generation Pipeline™ Vantage with Shield Technology™ launched in Canada

2021

- ✓ 4th Generation Pipeline™ Vantage with Shield Technology™ launched in Europe

2020

-  Shield 1yr study

2018

-  Premier study

2017

-  Pflex study

2016

-  PUF5 5 year follow-up results  
**CNS award winner**

2015

- ✓ 2nd Generation Pipeline™ Flex launched in Canada

2014

- ✓ 2nd and 3rd Generation Pipeline™ Flex & Shield Technology™ launched in Europe


-  Intrepid study

2013

-  Results of PUF5 5 year study

2012

-  Hong Kong experience

-  Ankara experience

2011

- ✓ 1st Generation Pipeline™ Device launched in Canada

-  Australian registry

2010

-  Pita study

2009

-  Buenos Aires experience

2008

- ✓ 1st Generation Pipeline™ device launched in Europe

-  Start of PUF5 5 year study

Product catalog number	Diameter (mm)	Length (mm)
PED3-021-250-10	2.5	10
PED3-021-250-12	2.5	12
PED3-021-250-14	2.5	14
PED3-021-250-16	2.5	16
PED3-021-250-20	2.5	20
PED3-021-275-12	2.75	12
PED3-021-275-14	2.75	14
PED3-021-275-16	2.75	16
PED3-021-275-20	2.75	20
PED3-021-300-12	3.0	12
PED3-021-300-14	3.0	14
PED3-021-300-16	3.0	16
PED3-021-300-20	3.0	20
PED3-021-325-12	3.25	12
PED3-021-325-14	3.25	14
PED3-021-325-16	3.25	16
PED3-021-325-20	3.25	20
PED3-021-350-12	3.5	12
PED3-021-350-14	3.5	14
PED3-021-350-16	3.5	16
PED3-021-350-20	3.5	20
PED3-021-350-25	3.5	25
PED3-027-350-12	3.5	12
PED3-027-350-14	3.5	14
PED3-027-350-16	3.5	16
PED3-027-350-20	3.5	20
PED3-027-350-25	3.5	25

Product catalog number	Diameter (mm)	Length (mm)
PED3-027-400-12	4.0	12
PED3-027-400-14	4.0	14
PED3-027-400-16	4.0	16
PED3-027-400-20	4.0	20
PED3-027-400-25	4.0	25
PED3-027-400-30	4.0	30
PED3-027-450-12	4.5	12
PED3-027-450-14	4.5	14
PED3-027-450-16	4.5	16
PED3-027-450-20	4.5	20
PED3-027-450-25	4.5	25
PED3-027-450-30	4.5	30
PED3-027-450-40	4.5	40
PED3-027-500-14	5.0	14
PED3-027-500-16	5.0	16
PED3-027-500-20	5.0	20
PED3-027-500-25	5.0	25
PED3-027-500-30	5.0	30
PED3-027-500-40	5.0	40
PED3-027-550-16	5.5	16
PED3-027-550-20	5.5	20
PED3-027-550-30	5.5	30
PED3-027-550-40	5.5	40
PED3-027-550-50	5.5	50
PED3-027-600-16	6.0	16
PED3-027-600-20	6.0	20
PED3-027-600-30	6.0	30
PED3-027-600-40	6.0	40
PED3-027-600-50	6.0	50

1. Medtronic Internal Study, D00422708 Rev. A , Competitive Test Report - Material Thrombogenicity Evaluation of Flow Diversion Devices.
2. Girdhar G, Li J, Kostousov L, Wainwright J, Chandler WL. In-vitro thrombogenicity assessment of flow diversion and aneurysm bridging devices. J Thromb Thrombolysis. 2015 Nov;40(4):437-43. doi: 10.1007/s11239-015-1228-0. PMID: 25975924.
3. D00422708 Rev A.
4. Girdhar G, Ubl S, Jahanbekam R, Thinamany S, Belu A, Wainwright J, Wolf MF. Thrombogenicity assessment of Pipeline, Pipeline Shield, Derivo and P64 flow diverters in an in vitro pulsatile flow human blood loop model. eNeurologicalSci. 2019 Jan 8;14:77-84.
5. Girdhar G, Andersen A, Pangerl E, Jahanbekam R, Ubl S, Nguyen K, Wainwright J, Wolf MF. Thrombogenicity assessment of Pipeline Flex, Pipeline Shield, and FRED flow diverters in an in vitro human blood physiological flow loop model. J Biomed Mater Res A. 2018 Dec;106(12):3195-3202.

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at [medtronic.ca](http://medtronic.ca) The Pipeline™ Vantage Embolization Device with Shield Technology™ is intended for use with or without embolic coils for the treatment of wide neck intracranial aneurysms (defined as having a large neck greater than 4 mm and/or a dome-to-neck ratio less than or equal to 1.5) that are not amenable to treatment with surgical clipping. Patients should be 21 years of age or older.

# Medtronic

**Medtronic Canada**  
 99 Hereford Street  
 Brampton, Ontario, L6Y 0R3  
 Toll-free: 800.268.5346  
 Tel: 905.460.3800

UC202202371aEC (CA-INS-0002)  
 © Medtronic 2022.  
 All rights reserved.